Verve Therapeutics Inc.

In News

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - TMX Newsfile

TMX Newsfile - Aug 03, 2026

Lilly Plans Phase II For VERVE-102 Gene-Editing Therapy After Early LDL-C Data - insights.citeline.com

insights.citeline.com - May 26, 2026

Lilly buys three vaccine makers; PCSK9 base editor shows promise - bioworld.com

bioworld.com - May 26, 2026

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PR Newswire

PR Newswire - Jun 17, 2025

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - investor.lilly.com

investor.lilly.com - Jul 25, 2025

Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine News

CRISPR Medicine News - Jun 17, 2025

Verve Therapeutics Acquired by Eli Lilly in $1 Billion Deal - Paul, Weiss

Paul, Weiss - Jul 25, 2025

Lilly to acquire Verve Therapeutics for $1.3 billion - Chemical & Engineering News

Chemical & Engineering News - Jun 18, 2025

Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy? - Yahoo Finance

Yahoo Finance - Apr 01, 2025

Verve Therapeutics Announces Positive Initial Data from the - GlobeNewswire

GlobeNewswire - Apr 14, 2025

Verve’s second swing at gene editing for heart disease shows early promise - biopharmadive.com

biopharmadive.com - Apr 14, 2025

Eli Lilly Gets Into The Gene-Editing Space With $1 Billion Takeout - Investor's Business Daily

Investor's Business Daily - Jun 17, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment